ArticleExperimental brain research2016
Near-infrared light (670 nm) reduces MPTP-induced parkinsonism within a broad therapeutic time window.
Article in Experimental brain research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Photobiomodulation for Parkinson's Disease in Animal Models: A Systematic Review.Biomolecules · 2020Pooled it
- Photobiomodulation Improves Serum Cytokine Response in Mild to Moderate COVID-19: The First Randomized, Double-Blind, Placebo Controlled, Pilot Study.Frontiers in immunology · 2022Trial
- Red and near-infrared light treatment can change the intensity of biophoton emissions in cell culture.Scientific reports · 2025Article
- Light buckets and laser beams: mechanisms and applications of photobiomodulation (PBM) therapy.GeroScience · 2025Review
- Effects of Photobiomodulation on Nervous System Disorders: A Narrative Review.Journal of lasers in medical sciences · 2025Review
- Photobiomodulation for Neurodegenerative Diseases: A Scoping Review.International journal of molecular sciences · 2024Article
- Parkinson's Disease and Photobiomodulation: Potential for Treatment.Journal of personalized medicine · 2024Review
- The effect of photobiomodulation on the brain during wakefulness and sleep.Frontiers in neuroscience · 2022Review
- Current application and future directions of photobiomodulation in central nervous diseases.Neural regeneration research · 2021Review
- Kolaviron ameliorates behavioural deficit and injury to striatal dopaminergic terminals via modulation of oxidative burden, DJ-1 depletion and CD45RMetabolic brain disease · 2020Article
- Mitochondria as a target for neuroprotection: role of methylene blue and photobiomodulation.Translational neurodegeneration · 2020Review
- Targeting Mitochondrial Impairment in Parkinson's Disease: Challenges and Opportunities.Frontiers in cell and developmental biology · 2020Review
- Photobiomodulation Mitigates Cerebrovascular Leakage Induced by the Parkinsonian Neurotoxin MPTP.Biomolecules · 2019Article
- Effect of Photobiomodulation in Rescuing Lipopolysaccharide-Induced Dopaminergic Cell Loss in the Male Sprague-Dawley Rat.Biomolecules · 2019Article
- Brain Photobiomodulation Therapy: a Narrative Review.Molecular neurobiology · 2018Review
- Photobiomodulation Therapy Improves Acute Inflammatory Response in Mice: the Role of Cannabinoid Receptors/ATP-Sensitive KMolecular neurobiology · 2018Article
- Remote tissue conditioning is neuroprotective against MPTP insult in mice.IBRO reports · 2018Article
- Photobiomodulation-induced changes in a monkey model of Parkinson's disease: changes in tyrosine hydroxylase cells and GDNF expression in the striatum.Experimental brain research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have shown previously that near-infrared light (NIr), when applied at the same time as a parkinsonian insult (e.g. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; MPTP), reduces behavioural deficits and offers neuroprotection. Here, we explored whether the timing of NIr intervention-either before, at the same time or after the MPTP insult-was important. Mice received MPTP injections (total of 50 mg/kg) and, at various stages in relation to these injections, extracranial application of NIr. Locomotor activity was tested with an open-field test, and brains were processed for immunohistochemistry. Our results showed that regardless of when NIr was applied in relation to MPTP insult, behavioural impairment was reduced by a similar magnitude. The beneficial effect of NIr was fast-acting (within minutes) and long-lasting (for several days). There were more dopaminergic cells in the NIr-treated MPTP groups than in the MPTP group; there was no clear indication that a particular combination of NIr treatment and MPTP injection resulted in a higher cell number. In summary, irrespective of whether it was applied before, at the same time as or after MPTP insult, NIr reduced both behavioural and structural measures of damage by a similar magnitude. There was a broad therapeutic time window of NIr application in relation to the stage of toxic insult, and the NIr was fast-acting and long-lasting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.